AVCO Stock Price, News & Analysis

Avalon GloboCare Corp. (NASDAQ: AVCO) has expanded its co-development program with MIT, focusing on groundbreaking technologies like CRISPR-based genome editing and QTY code-based chemokine receptors to combat cancer metastasis. Metastasis is a leading cause of cancer fatalities, and this partnership aims to block cancer cell signals that promote spread. The collaboration has already produced a prototype device to mitigate cytokine storms in cancer and COVID-19 patients. CEO David Jin emphasized a commitment to innovative cancer therapies.

Avalon GloboCare Corp. (NASDAQ: AVCO) has announced a collaboration with the University of Natural Resources and Life Sciences (BOKU) in Vienna to advance S-layer nanotechnology for various medical applications, including vaccines and therapeutic devices. A state-of-the-art research facility is being established at BOKU, led by experts in the field, to facilitate this development. Avalon aims to leverage this partnership to enhance its vaccine candidate against SARS-CoV-2 and other therapeutic solutions.

Avalon GloboCare Corp. (NASDAQ: AVCO) and Adial Pharmaceuticals, Inc. have formed a strategic collaboration for the worldwide distribution of the Assure/Fastep® and Assure/EcoStep® COVID-19 antibody tests, which are the first FDA authorized point-of-care tests using fingerstick blood samples. The FaStep COVID-19 IgG/IgM Rapid Test Device boasts an impressive accuracy of 98.6% for IgG and 92.9% for IgM, with results available in just 10 minutes. This collaboration aims to leverage Avalon's global distribution network to meet the increasing demand for rapid COVID-19 testing.

Avalon GloboCare Corp. (NASDAQ: AVCO) provided an update on its cellular therapy programs, notably the AVA-001 CAR T-cell therapy. This therapy, which targets relapsed/refractory B-cell lymphoblastic leukemia, successfully achieved a 90% complete remission rate in its Phase I trial. Avalon is expanding this trial to include patients with relapsed/refractory non-Hodgkin lymphoma. Additionally, the company has completed pre-clinical studies for its allogeneic MSC therapy candidate, CB-MSC-1, with plans to initiate first-in-human trials for acute graft-versus-host disease and ARDS in Q4 2020.

Avalon GloboCare Corp. (NASDAQ: AVCO) announced that Dr. David Jin, CEO, will participate in a virtual panel titled “New Approaches to COVID-19: Hidden Breakthroughs” on September 10, 2020. The panel will feature various leaders from the biopharmaceutical industry discussing their contributions to combating the COVID-19 pandemic. The event will be moderated by Christine Corrado from Proactive Investors. Interested investors can register for the event online. Avalon GloboCare is focused on cell-based technologies and therapeutics, particularly in immune effector cell therapy and COVID-19 diagnostics.

Avalon GloboCare Corp. (NASDAQ: AVCO) has completed a Phase I clinical study of AVA-001, a CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). The study reported a 90% complete remission (CR) rate among participants, with minimal toxicity and no severe adverse effects. Patients who achieved CR successfully proceeded to allogeneic bone marrow transplantation. The results will be presented on July 11, 2020, at the Lu Daopei Hematology Forum, showcasing potential advancements in cancer treatment.

Avalon GloboCare Corp. (NASDAQ: AVCO) has appointed Professor Uwe B. Sleytr to its Scientific and Clinical Advisory Board. Professor Sleytr, a leading expert in nanobiotechnology, has published over 420 scientific articles and made significant contributions to S-layer technology. His expertise is expected to enhance Avalon’s innovative projects, particularly in vaccine and drug delivery systems. The company aims to develop novel applications of S-layer technology integrating biomedical science and engineering, potentially advancing its clinical and scientific programs.